Adial pharmaceuticals chief medical officer and key opinion leaders to discuss the need for new alcohol use disorder treatments at the european society for biomedical research on alcoholism

Charlottesville, va., aug. 28, 2023 (globe newswire) -- adial pharmaceuticals, inc. (nasdaq: adil; adilw) (“adial” or the “company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that the chief medical officer of adial, bankole johnson, d.sc., m.d., and key opinion leaders jonathan chick, m.d., hannu alho, m.d., otto lesch, m.d., and giovanni addolorato, m.d., will be presenting at the european society for biomedical research on alcoholism (esbra), taking place september 1-3, 2023, in graz, austria.
ADIL Ratings Summary
ADIL Quant Ranking